JRCT ID: jRCTs051210101
Registered date:06/10/2021
Induction modified FOLFIRINOX for locally advanced pancreatic cancer
Basic Information
Recruitment status | Recruiting |
---|---|
Health condition(s) or Problem(s) studied | Pancreatic cancer |
Date of first enrollment | 05/11/2021 |
Target sample size | 29 |
Countries of recruitment | |
Study type | Interventional |
Intervention(s) | Interventional treatment of induction modified FOLFIRINOX followed by chemoradiation therapy with S-1 for borderline resectable and unresectable locally advanced pancreatic cancer |
Outcome(s)
Primary Outcome | Overall Response Rate |
---|---|
Secondary Outcome | Overall survival in each of BR and URLA, two-year survival rate, disease control rate, proportion of patients who received chemoradiotherapy, distant metastasis-free survival, conversion surgery rate, R0 resection rate in patients who performed pancreatomy, adverse event rate, dose intensity, treatment related motality rate/early mortality rate/incidence of severe adverse events(>Gr 3), surgery related motality rate in patients with performed pancreatomy, response evaluation in patients following additional CRT, contents of treatment after protcol treatment |
Key inclusion & exclusion criteria
Age minimum | >= 20age old |
---|---|
Age maximum | < 75age old |
Gender | Both |
Include criteria | 1) Pathologically-proven adenocarcinoma by diagnostic imaging 2) Without distant metastasis by chest and abdominal/pelvic MDCT 3) Diagnosed as borderline resectable or unresectable locally advanced pancreatic cancer according to international consensus 2017 of International Association of Pancreatology 4) Without ascites/pleural effusion by chest and abdominal/pelvic CT 5) Without severe gastrointestinal ulcer 6) Age from 20 to 75 years old 7) ECOG performance status of 0 or 1 8) Estimated survival more than three months 9) No prior chemotherapy, radiation therapy or surgical treatment for pancreatic cancer 10) Without interstitial pneumonia on chest CT 11) No watery stool 12) Without peripheral sensory or motor neuropathy (Gr > 1) 13) Adequate function of major organs 14) Written informed consent |
Exclude criteria | 1) Patients who prefer standard schedule FOFIRINOX or other chemotherapies including GnP if applicable 2) UGT genetic polymorphisms of homozygous UGT1A1*28 or UGT1A1*6 or heterozygous UGT1A1*6 and UGT1A1*28 3) Severe comorbidities [such as heart failure, renal failure, hepatic failure, paresis of intestine, illeus, poorly controlled diabetes(HbA1c>=10%)] 4) History of unstable ang ina pectoris or myocardial infarction within 6 months before registration. 5) Synchronous or metachronous malignancies except for early cancer 6) Infectious diseases (such as HIV, active tuberculosis, or bacterial infection) requiring systemic treatment, except for viral hepatitis and old pulmonary tuberculosis 7) Severe psychological disorder 8) Continuous systemic medication of corticosteroid or immunosuppressant 9) Pulmonary fibrosis or interstitial pneumonia 10) The history of adverse reactions to both of iodinated contrast media and gadolinium contrast media 11) Patients who are judged to be ineligible by investigators |
Related Information
Primary Sponsor | Ikezawa Kenji |
---|---|
Secondary Sponsor | Ohkawa Kazuyoshi,Takada Ryoji |
Source(s) of Monetary Support | |
Secondary ID(s) |
Contact
Public contact | |
Name | Ryoji Takada |
Address | 3-1-69 Otemae, Chuo-ku, Osaka Osaka Japan 541-8567 |
Telephone | +81-6-6945-1181 |
ryoji.takada@oici.jp | |
Affiliation | Department of Hepatobiliary and Pancreatic Oncology, Osaka International Cancer Institute |
Scientific contact | |
Name | Kenji Ikezawa |
Address | 3-1-69 Otemae, Chuo-ku, Osaka Osaka Japan 541-8567 |
Telephone | +81-6-6945-1181 |
ikezawa-ke@oici.jp | |
Affiliation | Department of Hepatobiliary and Pancreatic Oncology, Osaka International Cancer Institute |